Hepatocellular carcinoma is one of the most common malignant neoplasms in Korea and its prognosis with conventional treatment is poor(about 1~4 months). Although the tumor is small, surgical resection is often not indicated because of a
preexisting
advanced cirrhosis. multifocality, or site of the lesions. Recently transarterial embolization and chemoembolization are used for treatment of unresectable HCC. This study was undertaken to assess the therapeutic efficacy of hepatic arterial
infusion of
cisplatin alone(Group 1) or cisplatin combined with lipiodol or lipiodol and ADR(Group II). We analized the response rate, survival rate, and side effects according to the therapeutic modality. The response rates were 14%, 21% in group I, II and
there
was no significant difference between two groups. The survival rate at 6 months, 1 year for all 21 patients was 71%, 33% respectively and there was no significant difference according to therapeutic modalities. Adverse reactions from treatment
included
nausea, vomiting, fever, abdominal pain and elevation of transaminases. These were mild and tolerated by patients.
In conclusion, these results were not better than other chemoembolization with various chemotherapeutic agent, but the side effects were tolerated by patients and further study will be needed.
|